Efficacy of a Novel Lyophilized Arginine Lysine Polypeptide in the Treatment of Acne: In Vitro Experiments and a Split-Face Controlled Clinical Trial

Huanga S, Chen Y, Qiao Z, Hu Y, Zhang H, Zhang X, Huang Y and Xiang Q

Published on: 2021-01-01


Acne lesions are divided into three types: erythema, pigmentation, and scar, which can damage skin barrier function. And proliferations of keratinocytes are essential for maintenance of epidermal layers. The objective of this study was to assess the potential efficacy of a novel lyophilized cosmetic composed of arginine lysine polypeptide (LCAL) on improving skin condition. We evaluated the efficacy of LCAL in vitro by cell proliferation and adhesion assay, and in vivo by VISIA, CK and dermoscopy. The cell assays result showed that LCAL enhanced the proliferation of normal human primary fibroblast cells and adhesion of HaCaT cells. We also assessed the improvements of skin condition by sebum secretion, ITA and erythema index using CK at 0 (baseline), 2, and 4 week. Compared with the baseline, sebum secretion decreased by 40% and ITA increased at 4 wk?P<0.01?. Post-acne erythema was ameliorated, with erythema index decreasing by 18% after 4 wk?P<0.01?. The imaging captured using the VISIA and dermatoscope confirmed the reduction of post-acne erythema area and erythema index. These results indicated that LCAL was effective for improving skin barrier function which is a potential therapeutic strategy in improving skin barrier function after acne.